MedTrace Logo

LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)

NCT04889404 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2026-01-14

No results posted yet for this study

Summary

To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.

Conditions

  • Pancreatic Neoplasms

Sponsors & Collaborators

Principal Investigators

  • Toshimitsu Tokimoto · Astrazeneca KK

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-22
Primary Completion
2025-02-06
Completion
2025-02-06

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04889404 on ClinicalTrials.gov